Last reviewed · How we verify
Abatacept Prefilled Syringe
Abatacept Prefilled Syringe, marketed by Lille Catholic University, is an established product in the therapeutic landscape. The key composition patent expires in 2028, providing a significant period of market exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Abatacept Prefilled Syringe |
|---|---|
| Also known as | Orencia |
| Sponsor | Lille Catholic University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease (PHASE2)
- Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis (PHASE2)
- Abatacept in Patients With Birdshot HLA A29 Uveitis (PHASE2)
- Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route (PHASE1)
- Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders (PHASE4)
- A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV) (PHASE4)
- A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abatacept Prefilled Syringe CI brief — competitive landscape report
- Abatacept Prefilled Syringe updates RSS · CI watch RSS
- Lille Catholic University portfolio CI